A low-profile startup in Boston backed by some marquee venture groups has posted positive data from a Phase III study of its biosimilar of Remicade, a blockbuster rheumatoid arthritis drug.
As research universities around the world look to put their labs to lucrative use by launching CROs, Duke University has nailed down another development deal, teaming up with the International Stem Cell Corporation on a Parkinson's disease treatment.
Dublin, CA-based Astex Pharmacueticals revealed Wednesday morning that its small molecule SGI-110 showed "clear activity" in a Phase II trial of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome.
An NIH-sponsored study of Gilead's sofosbuvir combined with ribavirin demonstrated that the experimental therapy provided a "safe and effective" interferon-free approach for even some of the toughest hepatitis C cases.
Investigators say that lampalizumab slowed progression of AMD in patients with advanced disease, shrinking the area of geographic atrophy by 20.4%. AMD is a leading cause of blindness and major market opportunity for the drug giant, which has executed a sequence of big advances in R&D.
Shares of Acura Pharmaceuticals took a drubbing overnight after the biotech reported the failure of a midstage study of a painkiller designed to reduce its appeal for abuse.
The treatment, Firdapse, is marketed in Europe by BioMarin and is now in a Phase III study designed to win an FDA approval. And the company's shares, battered last fall after its lead drug flopped in a Phase IIb trial for cocaine addiction, instantly zoomed up 48% on the news.
In 2009, Sanofi made its play for the seniors flu vaccine market by introducing Fluzone High-Dose. After running a trial of 30,000 people aged 65 and older, the company is ready to go back to FDA to seek a new label for the vaccine.
Shares of Rigel Pharmaceuticals took a dive this morning, dropping 17% after the South San Francisco-based biotech announced that it is burying a program for allergic asthma after its drug R343 flunked a midstage study.
Switzerland's Psi is reaching into India's clinical research market, opening up shop in the country and continuing its global expansion.